Tumor suppressor activity of profilin requires a functional actin binding site.
Profilin 1 (PFN1) is a regulator of the microfilament system and is involved in various signaling pathways. It interacts with many cytoplasmic and nuclear ligands. The importance of PFN1 for human tissue differentiation has been demonstrated by the findings that human cancer cells, expressing conspicuously low PFN1 levels, adopt a nontumorigenic phenotype upon raising their PFN1 level. In the present study, we characterize the ligand binding site crucial for profilin's tumor suppressor activity. Starting with CAL51, a human breast cancer cell line highly tumorigenic in nude mice, we established stable clones that express PFN1 mutants differentially defective in ligand binding. Clones expressing PFN1 mutants with reduced binding to either poly-proline-stretch ligands or phosphatidyl-inositol-4,5-bisphosphate, but with a functional actin binding site, were normal in growth, adhesion, and anchorage dependence, with only a weak tendency to elicit tumors in nude mice, similar to controls expressing wild-type PFN1. In contrast, clones expressing a mutant with severely reduced capacity to bind actin still behaved like the parental CAL51 and were highly tumorigenic. We conclude that the actin binding site on profilin is instrumental for normal differentiation of human epithelia and the tumor suppressor function of PFN1.
Wittenmayer
Nina
N
Cell Biology, Zoological Institute, Technical University of Braunschweig, D-38092 Braunschweig, Germany.
Jandrig
Burkhard
B
Rothkegel
Martin
M
Schlüter
Kathrin
K
Arnold
Wolfgang
W
Haensch
Wolfgang
W
Scherneck
Siegfried
S
Jockusch
Brigitte M
BM
D008841:Actin Cytoskeleton / Q000378:metabolism; D000199:Actins / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D002448:Cell Adhesion; D002455:Cell Division; D045744:Cell Line, Tumor; D002465:Cell Movement; D003094:Collagen / Q000494:pharmacology; D003285:Contractile Proteins / Q000502:physiology*; D003593:Cytoplasm / Q000378:metabolism; D004338:Drug Combinations; D004848:Epithelium / Q000378:metabolism; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D015151:Immunoblotting; D007797:Laminin / Q000494:pharmacology; D008024:Ligands; D051379:Mice; D008819:Mice, Nude; D008840:Microfilament Proteins / Q000502:physiology*; D009154:Mutation; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000378:metabolism*; D010641:Phenotype; D019269:Phosphatidylinositol 4,5-Diphosphate / Q000737:chemistry; D017354:Point Mutation; D051304:Profilins; D011509:Proteoglycans / Q000494:pharmacology; D011994:Recombinant Proteins / Q000737:chemistry; D015398:Signal Transduction; D013997:Time Factors; D014162:Transfection
D000199:Actins; D003285:Contractile Proteins; D004338:Drug Combinations; D007797:Laminin; D008024:Ligands; D008840:Microfilament Proteins; C495738:PFN1 protein, human; C495739:Pfn1 protein, mouse; D019269:Phosphatidylinositol 4,5-Diphosphate; D051304:Profilins; D011509:Proteoglycans; D011994:Recombinant Proteins; C059485:matrigel; D003094:Collagen